Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3Fluart
- Development stage
- Phase 1
- Lead developer
- Fluart Innovative Vaccines
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Injection
01
Overview
**3Fluart** is a seasonal trivalent influenza vaccine developed and manufactured by Fluart Innovative Vaccines. It is an intramuscular suspension containing inactivated, adjuvanted whole influenza virions representing two influenza A subtypes, A/H1N1 and A/H3N2, and one influenza B component selected for the applicable seasonal recommendations. Each 0.5 mL dose contains 6 micrograms of haemagglutinin per strain. The vaccine is intended to induce active immunity against influenza and is authorized for prevention of seasonal influenza in people aged 3 years and older.
- Brand names
- 3Fluart
- Other names
- 3Fluart suspension for injection
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on 3Fluart.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 3Fluart.